Published in

Elsevier, Nuclear Medicine and Biology, 6(36), p. 591-603

DOI: 10.1016/j.nucmedbio.2009.03.006

Links

Tools

Export citation

Search in Google Scholar

Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation

Journal article published in 2009 by Eftychia Koumarianou, Renata Mikołajczak, Dariusz Pawlak, Xhristos Zikos, Pinelopi Bouziotis, Piotr Garnuszek, Urszula Karczmarczyk, Michał Maurin ORCID, Spyridon C. Archimandritis
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

The aim of the study was to compare in vitro and in vivo a novel DOTA-chelated bombesin (BN) analog of the amino acid sequence, QRLGNQWAVGHLM-CONH2 (BN[2–14]NH2), labeled with 90Y and 177Lu, for its potential use in targeted radiotherapy of tumors expressing gastrin releasing peptide (GRP) receptors. The same amino acid sequence, but with different chelator, referred as BN1.1 (Gly-Gly-Cys-Aca-QRLGNQWAVGHLM-CONH2), has already been studied and reported; however, the DOTA-chelated one, suitable for labeling with M+3 type radiometals, was not yet described.